By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating from Detroit, Michigan, by NewsRx correspondents, research stated, "Oncolytic adenovirus-mediated suicide gene therapy has been shown to improve local tumor control in preclinical tumor models and in the clinic. Although local tumor control is important, for most human cancers, new therapies must also target metastatic disease if they are to have an impact on survival."
Our news editors obtained a quote from the research from Henry Ford Health Systems, "Here, we test the hypothesis that adding cytokine gene therapy to our multimodal platform improves both local and metastatic tumor control in a preclinical model of prostate cancer. An oncolytic adenovirus (Ad5-yCD/mutTK(SR39)rep-mIL12) expressing two suicide genes and mouse interleukin-12 (IL-12) was generated. Relative to an adenovirus lacking IL-12 (Ad5-yCD/mutTK(SR39)rep), Ad5-yCD/mutTK(SR39)rep-mIL12 improved local and metastatic tumor control in the TRAMP-C2 prostate adenocarcinoma model, resulting in a significant increase in survival. Ad5-yCD/mutTK(SR39)rep-mIL12 resulted in high levels of IL-12 and interferon gamma in serum and tumor, increased natural killer (NK) and cytotoxic T-lymphocyte lytic activities, and the development of tumor-specific antitumor immunity. Immune cell depletion studies indicated that both the innate and adaptive arms of immunity were required for maximal Ad5-yCD/mutTK(SR39)rep-mIL12 activity."
According to the news editors, the research concluded: "The results demonstrate that the addition of IL-12 significantly improves the efficacy of oncolytic adenovirus-mediated suicide gene therapy and provide the scientific basis for future trials targeting locally aggressive cancers."
For more information on this research see: Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Therapy, 2013;20(12):1131-1139. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)
The news editors report that additional information may be obtained by contacting S.O. Freytag, Henry Ford Hlth Syst, Dept. of Radiat Oncol, Detroit, MI 48202, United States. Additional authors for this research include K.N. Barton and Y. Zhang (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Detroit, Michigan, Genetics, Oncology, Peptides, Proteins, Cytokines, Adenovirus, United States, Bioengineering, Interleukin-12, Prostate Cancer, Pre-Trial Research, Cancer Gene Therapy, Prostatic Neoplasms, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC